Clinical Trial Update: Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating an 8 mg aflibercept (EYLEA) prefilled syringe for diabetic macular edema and neovascular age-related macular degeneration has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Status: COMPLETED